|1.||Folkman, Judah: 18 articles (06/2010 - 10/2002)|
|2.||Griffioen, Arjan W: 13 articles (04/2015 - 01/2003)|
|3.||Jain, Rakesh K: 10 articles (09/2015 - 01/2005)|
|4.||Ribatti, Domenico: 8 articles (03/2015 - 02/2003)|
|5.||Wen, Patrick Y: 8 articles (06/2013 - 06/2003)|
|6.||Dahut, William L: 7 articles (01/2014 - 02/2007)|
|7.||Figg, William D: 7 articles (09/2012 - 05/2002)|
|8.||McDonald, Donald M: 7 articles (07/2011 - 09/2002)|
|9.||Heymach, John V: 6 articles (12/2015 - 05/2005)|
|10.||Davidoff, Andrew M: 6 articles (09/2015 - 02/2005)|
01/01/2015 - "Besides commercially available angiogenic inhibitors, numerous anti-angiogenic therapies have been developed to limit tumor growth, although, most of them have not proved beneficial in terms of long-term survival. "
01/01/2011 - "Although angiogenesis inhibitors are available in the clinic, their efficacy against most cancers is modest due in part to the existence of alternative and compensatory signaling pathways. "
11/01/2009 - "The recent addition of angiogenesis inhibitors to the cancer treatment armamentarium represents an attractive option, especially since these agents have been shown to be most effective when combined with other therapies. "
02/01/2015 - "Angiogenesis inhibitors are beneficial for the prevention and treatment of angiogenesis-dependent diseases including cancer. "
06/08/2009 - "Angiogenesis inhibitors are beneficial for the prevention and treatment of angiogenesis-dependent diseases including cancer. "
|2.||Breast Neoplasms (Breast Cancer)
06/01/2013 - "Numerous clinical studies for several antiangiogenic agents have recently been conducted in breast cancer patients and have shown clinically significant improvement in outcomes. "
01/01/2014 - "To date, the overall observed clinical improvements are unconvincing, and further research is required to demonstrate the efficacy of anti-angiogenic drugs in breast cancer treatments. "
02/01/2015 - "Angiogenesis inhibitors and antivascular agents may prove useful in the treatment of breast cancer. "
01/01/2014 - "The efficacy of anti-angiogenic drugs in adjuvant therapy or as neo-adjuvant treatment has been estimated in clinical trials of advanced breast cancer. "
02/21/2012 - "However, the efficacy of such treatments, especially in breast cancer patients, has been called into question, as recent clinical trials reveal only limited effectiveness of antiangiogenic agents in prolonging patient survival. "
|3.||Prostatic Neoplasms (Prostate Cancer)
02/01/2010 - "There are now multiple early-phase clinical trials of antiangiogenic agents alone or in combination in prostate cancer. "
12/01/2009 - "The findings of these and future studies will ultimately determine the role of angiogenesis inhibitors in the treatment of prostate cancer."
12/01/2009 - "Trials studying antiangiogenic agents have been conducted in localized and advanced prostate cancer. "
05/01/2006 - "This review will highlight the clinical experience to date with angiogenesis inhibitors in prostate cancer and the ongoing studies."
05/01/2014 - "Although no angiogenesis inhibitors have been approved for patients with metastatic prostate cancer, therapies that target new blood vessel formation are still an emerging and promising area of prostate cancer research. "
|4.||Neoplasm Metastasis (Metastasis)
01/01/2008 - "In the metastatic model treatment with angiogenic inhibitors induced a significant reduction in the size and number of lung metastases with additive effects when factors were used in combination. "
01/01/2014 - "Despite ongoing clinical trials, the efficacy of anti-angiogenic drugs for the treatment of brain metastases (BM) is still questionable. "
06/01/2010 - "Some preclinical studies have also shown that antiangiogenic agents prevent metastasis by modulating the premetastatic niche. "
06/01/1998 - "Likewise, a number of recent animal studies have shown that angiogenesis inhibitors can prevent metastasis and shrink established experimental tumours to small dormant microtumours. "
01/01/2011 - "Metastasis dormancy is characterized by a balance between cell proliferation and apoptosis and is thought to be controlled by increased apoptosis, indirectly induced by angiogenesis inhibitors. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/2015 - "An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer."
01/01/2015 - "Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials."
05/01/2015 - "We aimed to quantify the overall efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer (NSCLC). "
05/01/2015 - "Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis."
01/01/2015 - "Several angiogenesis inhibitors have been developed as potential therapies for non-small-cell lung cancer (NSCLC). "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|4.||Biological Markers (Surrogate Marker)
|6.||O-(chloroacetylcarbamoyl)fumagillol (TNP 470)
|8.||SU 6668 (SU6668)
|9.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Molecular Targeted Therapy